Concord Biotech Limited will hold a board meeting on Tuesday, October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026, along with a limited review report from its statutory auditors. The trading window for the company's securities will remain closed for 48 hours after the declaration of the financial results, as previously communicated in a letter dated September 28, 2026.